Alligator Bioscience AB
FSX
Closed
Jul 24, 2026
Day's Range
0.00010052 wk Range
0.000100Key Statistics
Symbol
7AL0
Name
Alligator Bioscience AB
Currency
EUR
Exchange
FSX
High
0.000099999997
Low
0.000099999997
Open
‪0.000100‬
Last
‪0.000100‬
Market Cap
62.81K
Pe Ratio
‪0.000020‬
Volume
0
Average Volume
1.64K
Dividend Yield
‪0.00%‬
Change
0.00
Percent Change
0.00
Timestamp
2026-07-24
Close
0.000099999997
Today Range Start
‪0.000100‬
Today Range End
‪0.000100‬
52 Week Range Start
‪0.000100‬
52 Week Range End
‪0.5004‬
Type
Stocks
Country
Sweden
Historical Data - 7AL0 - Alligator Bioscience AB
Historical Data
Market Cap - 7AL0 - Alligator Bioscience AB
Market Cap
2026-07-23
62.81K
2026-07-22
62.81K
2026-07-21
23.93M
2026-07-20
62.81K
2026-07-17
62.81K
2026-07-16
62.81K
2026-07-15
62.81K
2026-07-14
62.81K
2026-07-13
62.81K
2026-07-10
62.81K
Splits - 7AL0 - Alligator Bioscience AB
Splits
2025-04-07
0.001-for-1 split (1000)
Earnings - 7AL0 - Alligator Bioscience AB
Earnings
Balance Sheet - 7AL0 - Alligator Bioscience AB
Balance Sheet
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
 Assets | 110.60M | 9.77M |
| Liabilities | 103.74M | 22M |
| Shareholders Equity | 6.85M | -12.23M |
Cash Flow - 7AL0 - Alligator Bioscience AB
Cash Flow
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Operating Activities | - | - |
| Investing Activities | - | - |
| Financing Activities | - | - |
| End Cash Position | 62.19M | 6.02M |
| Income Tax Paid | - | - |
| Interest Paid | - | - |
| Free Cash Flow | -157.44M | -19.90M |
Income Statement - 7AL0 - Alligator Bioscience AB
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 514K | 5.41M |
| Cost of Goods | - | - |
| Gross Profit | - | - |
| Operating Expense | - | - |
| Operating Income | -121.66M | -17.77M |
| Non-Operating Interest | - | - |
| Other Income Expense | - | - |
| Pre Tax Income | -51.35M | -21.91M |
| Income Tax | 0 | 0 |
| Net Income | -51.35M | -21.91M |
| EPS Basic | -1.87 | -13.155746 |
| EPS Diluted | -1.87 | -13.155746 |
| Basic Shares Outstanding | 27.52M | 1.67M |
| Diluted Shares Outstanding | 27.52M | 1.67M |
| Ebit | -7.08M | -20.06M |
| Ebitda | -115.43M | -11.86M |
| Net Income Continuous Operations | -105.82M | -21.46M |
| Minority Interests | - | - |
| Preferred Stock Dividends | 0 | 0 |
Profile - 7AL0 - Alligator Bioscience AB
Profile
Mic Code
XFRA
Sector
Healthcare
Industry
Biotechnology
Employees
11
Alligator Bioscience AB is a clinical-stage biotechnology company focused on developing tumor-directed immuno-oncology antibody drugs, particularly those targeting the CD40 receptor pathway. Its primary purpose is to activate the patient's immune system directly within the tumor microenvironment, overcoming immune suppression to elicit potent anti-tumor responses. The company's lead asset, mitazalimab, a CD40 agonist, is advancing toward Phase 3 development in first-line metastatic pancreatic cancer after promising Phase 2 OPTIMIZE-1 trial results, including unprecedented 24-month survival outcomes in this challenging indication. Alligator Bioscience AB maintains a robust pipeline of mono- and bispecific antibody programs designed for localized immune activation, balancing efficacy and safety. Founded in 2001 and headquartered at Medicon Village in Lund, Sweden, the company plays a significant role in advancing immunotherapies for hard-to-treat cancers, contributing to innovation in the biotechnology sector.
Profile Details
Type
Common Stock
Address
Medicon Village
City
Lund
Zip
223 81
Country
Sweden
Phone
46 4 65 40 82 00
